The Impact of the COVID-19 Pandemic on the Future of Science Careers
Himasha M. Perera,* Wezley C. Griffin, Rumasha N. T. Kankanamage, and Lakindu S. Pathira Kankanamge

ABSTRACT: As COVID-19 swept across the world, it created a global pandemic and an unpredictable and challenging job market. This article discusses the future of the 2020–2021 job market in both academia and industry in the midst and aftermath of this pandemic.

The American Chemical Society (ACS) Division of Chemical Toxicology (TOXI) held a career panel at the virtual ACS conference that discussed the impact of the COVID-19 pandemic on the academic and industrial job markets in 2020–2021. The panel included experienced scientists from both academia and industry: Dr. F. Peter Guengerich (Tadashi Inagami Chair in Biochemistry, Vanderbilt School of Medicine), Dr. Nicholas Meanwell (Vice President, Bristol-Myers Squibb), Dr. Melissa Schutten (Principal Scientist-Pathologist, Genentech), and Dr. Maureen McKeague (Assistant Professor, McGill University). The panel was hosted by Dr. Michael Trakselis (Professor and Director of Graduate Affairs, Baylor University), the Vice Chair of ACS TOXI 2020.

Hiring Freezes: The New Normal in Academia. The economic plunge induced by the COVID-19 pandemic has created a career calamity in academia, resulting in a funding crisis. Most universities across the US and Canada have announced hiring freezes for new faculty lines, which will make securing an academic position and research funding extremely challenging in the coming year. However, as mentioned by Dr. Guengerich, there are always targeted opportunities at both the junior and senior levels for outstanding candidates. Most of these opportunities arise from informal discussions, social networking, and exposure at conferences. Thus, establishing and maintaining a broad network of scientists is deemed important, especially during this pandemic. As highlighted by Drs. Guengerich and McKeague, the silver lining in this challenging job market is that there seems to be no apparent reduction in the number of postdoc positions advertised on social media platforms. The panelists strongly recommended becoming active on Twitter, as it has become a prominent platform in advertising job postings in academia. However, Dr. Guengerich expressed concern that the academic job outlook for the 2020–2021 year will be more challenging than that brought on by the 2008 financial crisis because universities are challenged on all fronts with decreasing student enrollments, online classes, and decreased research output.

The pathway to obtaining funding for academic research has always been challenging, noted Dr. Guengerich. Federal funding for research appears to be unaffected by the pandemic and continues at a stable level. However, the panel went on to mention that funding provided by philanthropic charities will take a hit. Financial contributions and social fundraising events have been significantly limited by the pandemic, leading to decreased support from several agencies.

No Signs of Alarm in the Biopharmaceutical Industry. Compared to academia, the industrial and biopharmaceutical job markets appear promising in terms of the availability of open positions and hiring. While it is somewhat challenging to predict the future job market, currently there are no apparent hiring freezes in industry. With increasing demand for COVID-19 testing kits, Genentech (owned by Roche diagnostics) has been busy designing and validating COVID-19 tests. This has expanded job opportunities within many companies, Genentech included, who are actively hiring, says Dr. Schutten.

One fortuitous outcome from the recent COVID-19 pandemic is that more collaborative opportunities between biopharma and industrial companies in discovering, validating, and producing a new vaccine are beginning to emerge. As these attempts become promising, industries will come together to manufacture the vaccine to make it broadly available. This will amplify the job opportunities in several different fields such as toxicology, chemistry, and commercial manufacturing.

Exciting Trends Transforming the Future of Biopharma. Apart from the new avenues that have been created due to COVID-19, the panelists also shared their insights on other influential biopharma and industrial trends to be on the lookout for in the next 5 years. According to both Drs.
Meanwell and Schutten, the concept of ligand-induced degradation is an exciting, emerging frontier in medicinal chemistry. Proteolysis TArgeting Chimera (PROTAC) is a major focus for several companies as a means of ligand-induced degradation and promises to make an impact in the near future. PROTAC is a proteasomal targeting system where a ternary complex, consisting of two ligands connected by a linker, can artificially signal proteins for degradation. One ligand binds to a target protein and the other binds to a ubiquitin ligase. PROTAC polyubiquitinylates the target protein and signals it for degradation by the proteasome. This new frontier in chemistry has the potential to tackle numerous biological targets that are considered undruggable and allows for the targeted control of protein levels.

Establishing Your Career Path. The panelists were asked how a new Ph.D./Postdoc should envision their career path in industry for the first 5−10 years. Specifically, are positions relatively stable, or do most people jump between biotech startup companies early in their career? The panelists shared that the career paths in industry are generally quite stable. The San Francisco Bay area, the industrial hotspot, is filled with startups and some bigger companies with larger biotech portfolios. In these large organizations, there are a diverse group of people where anyone can gain good mentorship, training, and valuable experience. However, there is also a tendency to transition from startup to startup, not because of job instability, but because of the exciting new opportunities.
that will allow people to maximize their contributions to science and learn new techniques and applications.

Networking plays a pivotal role to effectively get applicants’ foot in the door in both academic and industrial sectors, says Dr. McKeague. The recognition gained through networking moves applications to the top of the pile for a second look and become a standout among all the applicants. Although there is a role for recruiters in finding people for more senior professions, new Ph.D.s are regularly hired directly through a role for recruiters in becoming a standout among all the applicants. Although there is moves applications to the top of the pile for a second look and foot in the door in both academic and industrial sectors, says science and learn new techniques and applications. that will allow people to maximize their contributions to

Chemical Research in Toxicology pubs.acs.org/crt

■ AUTHOR INFORMATION

Corresponding Author

Himasha M. Perera — Department of Chemistry and Biochemistry, Baylor University, Waco, Texas 76798, United States; orcid.org/0000-0003-1533-9640; Email: Himasha_Perera@baylor.edu

Authors

Wesley C. Griffin — Department of Chemistry and Biochemistry, Baylor University, Waco, Texas 76798, United States

Rumasha N. T. Kankanamage — Department of Chemistry, University of Connecticut, Storrs, Connecticut 06269, United States

Lakindu S. Pathira Kankanamge — Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States; orcid.org/0000-0002-2836-9489

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.chemrestox.0c00436

Notes

The authors declare no competing financial interest.

■ REFERENCES

(1) Scudellari, M. (2019) Protein-slaying drugs could be the next blockbuster therapies. Nature 567, 298–300.

(2) Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., and Rao, Y. (2019) PROTACs: great opportunities for academia and industry. Signal Transduction Targeted Ther. 4, 64.